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Abstract
In the United States (US), there are high levels of disengagement along the HIV care continuum. 
We sought to characterize the heterogeneity in research studies and interventions to improve care 
engagement among people living with diagnosed HIV infection. We performed a systematic 
literature search for interventions to improve HIV linkage to care, retention in care, reengagement 
in care and adherence to antiretroviral therapy (ART) in the US published from 2007-mid 2015. 
Study designs and outcomes were allowed to vary in included studies. We grouped interventions 
into categories, target populations, and whether results were significantly improved. We identified 
152 studies, 7 (5%) linkage studies, 33 (22%) retention studies, 4 (3%) reengagement studies, and 
117 (77%) adherence studies. ‘Linkage’ studies utilized 11 different outcome definitions, while 
‘retention’ studies utilized 39, with very little consistency in effect measurements. The majority 
(59%) of studies reported significantly improved outcomes, but this proportion and corresponding 
effect sizes varied substantially across study categories. This review highlights a paucity of 
assessments of linkage and reengagement interventions; limited generalizability of results; and 
substantial heterogeneity in intervention types, outcome definitions, and effect measures. In order 
to make strides against the HIV epidemic in the US, care continuum research must be improved 
and benchmarked against an integrated, comprehensive framework.
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Introduction
In 2015, the White House released an updated comprehensive National HIV/AIDS Strategy 
(NHAS) [1], and outlined specific measures to assess progress along the HIV care 
continuum. It is increasingly recognized that effective approaches to ending HIV in the 
United States (US) will require comprehensive strengthening of multiple components of the 
HIV care continuum [2]. While recent models have suggested that improved retention of 
HIV-positive persons in care is critical to reducing transmission [3, 4], large numbers of 
people living with HIV (PLHIV) in the US remain unaware of their infection (~13% of all 
PLHIV), unlinked to care, disengaged from care (~61% of all PLHIV), incompletely 
adherent to antiretroviral therapy (ART), and virologically unsuppressed (~70% of all 
PLHIV) [5, 6]. While the NHAS characterizes federal and local implementation strategies to 
address these gaps, it does not specify particular programs to implement in given areas with 
particular populations. To date, the majority of scientific effort has been dedicated to 
improving each stage of the HIV care continuum independently—each of which has been 
reviewed in recent years, including by the Centers for Disease Control and Prevention’s 
Prevention Research Synthesis (PRS) team [7–13]. The PRS project provides a vital 
resource for the identification of evidence-based interventions to improve steps of the HIV 
care continuum. However, these evidence-based interventions have variability in their 
magnitude of effect, sustainability of effects, costs (or lack of assessment of costs) and 
heterogeneity in study design and outcomes assessments.
The next step in designing a comprehensive approach to HIV prevention and engagement is 
to build upon prior work [13] by synthesizing the literature on interventions to strengthen the 
HIV continuum of care, in order to describe the heterogeneity of studied interventions’ 
approaches, costs, study designs, and study outcomes. Characterizing these heterogeneities 
will lay the foundation for decision-makers to develop a common framework for assessing 
HIV care continuum interventions, while helping researchers to better understand the 
evidence gaps we most urgently need to fill. For example, the extent to which currently 
studied interventions could achieve the NHAS goals is unknown, and without a common 
framework it will remain a challenge to evaluate.
As such, we performed a broad-based systematic review of all published interventions 
designed to strengthen the HIV care continuum after HIV diagnosis, with the aim of 
collecting evidence for prioritization of interventions, direction of future research, and 
evaluation of interventions to improve health outcomes and prevent HIV across the 
continuum of care.
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Methods
We conducted a systematic review of English language literature to comprehensively 
characterize interventions designed to improve HIV care engagement in the US after HIV 
diagnosis. We conducted separate searches for the following care continuum steps: initial 
linkage to care (for those newly diagnosed with HIV), care retention (for those currently in 
care), care reengagement (for those previously in care), and medication adherence while on 
ART (for those in care and prescribed ART) (see Fig. 1 for a schematic of the steps of the 
HIV care continuum addressed). Our primary objectives were to characterize and describe 
the spectrum of HIV care continuum interventions for different target populations, and to 
characterize the heterogeneity of outcomes measured among such studies. Our secondary 
objectives were to describe the efficacy and whether costs are reported for identified 
interventions.
Search Strategy and Study Selection
We systematically searched MEDLINE and EMBASE for citations published from 1 Jan 
2007 to 17 June 2015. A list of keywords was created around the domains of interest (see 
Appendix 1 for complete search strategy). The reference lists of 64 reviews found in our 
search were evaluated to identify any manuscripts meeting inclusion criteria that were not 
found in our search strategy.
The overall target population for the review was people living with diagnosed HIV infection 
in the US. We included all study participants regardless of age, gender, and ethnicity. We 
included studies that had explicitly defined study populations exposed to an intervention, 
and a comparator population that did not receive an intervention. This review did not seek to 
evaluate any specific intervention, and interventions included were any biomedical, 
behavioral, health system, or policy strategy that sought to increase engagement in the four 
areas listed above. We excluded studies evaluating or comparing specific ART regimens or 
dosing frequencies, those without a comparator group, those without a defined intervention, 
and those without at least one quantifiable outcome (i.e., qualitative analyses). We included 
prospective and retrospective cohort studies, pre-post studies, and randomized clinical trials 
(RCTs); we excluded cross-sectional studies, mathematical modeling studies, and studies 
without empirically collected patient data. We included any study-defined outcomes and 
measures of intervention efficacy and quantified the variability in these outcome definitions.
Two reviewers independently evaluated titles, and then performed a review of abstracts to 
identify potentially relevant studies. We then conducted full-text review according to the 
established inclusion and exclusion criteria. Two reviewers abstracted the following data 
from all included studies: dates of study, location, intervention and comparator description, 
target population, eligibility criteria, study design, sample size, description of outcome 
measures, results, and any cost data. We utilized the Cochrane Collaboration’s tool to assess 
quality of included RCTs [14] and the Newcastle-Ottawa quality assessment scale for 
observational studies [15].
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Data Analysis
Studies were classified based on the HIV care continuum step that the intervention sought to 
modify. We defined linkage studies as those targeting a population newly diagnosed with 
HIV and not yet in care, in which the outcome included time required to initiate care or 
percentage of the population establishing initial care within a defined period of time after 
diagnosis. Retention in care studies were those in which the target population was in care at 
the intervention initiation, with outcomes measuring any event that provided evidence of 
care engagement. By contrast, we defined reengagement studies to be those in which the 
target population was previously HIV-diagnosed (not newly diagnosed) but not currently 
engaged in HIV care. Adherence studies were defined to include populations currently in 
care and prescribed ART, with outcomes dependent on the degree of receipt and/or 
medication adherence to daily ART. If a publication included outcomes that fit our 
definitions for more than one care continuum step, it was included in multiple categories.
Anticipating significant heterogeneity of study outcomes within and across stages of the care 
continuum, we did not seek to perform meta-analyses. Rather, we approached 
summarization and characterization of data along the following domains. First, for each step 
in the care continuum we sought to qualitatively categorize interventions based on 
similarities of modality or approach utilized. We grouped education and behavioral/
counseling interventions separately with systematic (non-individualized) interventions 
described as education, while behavioral/counseling interventions were those that appeared 
to be centered on a client-specific exchange. We additionally categorized the target 
populations included within intervention studies: general population, people who use drugs 
(PWUD) (any use), men who have sex with men (MSM), prison/jail, adolescents/youth, 
women, homeless population, other, and when possible racial/ethnic minorities. Next, we 
quantified the number of different study outcomes and effect measures reported across 
studies. Many studies reported multiple outcomes, and these were counted separately. 
Finally, we summarized intervention efficacy by characterizing the study outcomes as being 
significantly improved or not, as defined by each individual study (a study counted as having 
significant results if at least one outcome was statistically significantly improved in study 
defined statistical analysis). When possible we compiled effect sizes in tabular format and/or 
in descriptive analysis. For each step of the HIV care continuum, we additionally assessed 
whether study outcomes could be compared to metrics outlined in the updated NHAS 
progress indicators (i.e. % linking to care within one month, % retained in care among those 
diagnosed, % virally suppressed among those diagnosed). Finally, we also reported on 
whether costs and cost-effectiveness data were provided.
Results
Our search yielded 5786 articles, of which 152 were included in the final analysis (Fig. 1 
and Supplemental Figure). Among included studies, 7 (5%) presented data on ‘linkage’, 33 
(22%) on ‘retention‘, 4 (3%) on ‘reengagement’, and 117 (77%) on ‘adherence’, with some 
categorized to multiple care continuum steps (Supplemental Figure).
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Linkage
Among 7 studies that targeted newly diagnosed HIV-positive persons (shown in Table 1), 4 
(57%) were cohort studies while the remainder utilized a pre-post study design; there were 
no RCTs identified. None of the 7 ‘linkage’ studies assessed costs of their intervention. The 
target population in each of the studies (7/7, 100%) was the general population of PLHIV, 
without further targeting of risk groups.
Overall, we found no two studies that measured identical linkage to care outcomes 
(Supplemental Table), and no studies (0/7, 0%) reported data that would allow direct 
comparison against the current NHAS progress indicator for linkage to care targets (i.e. 
percent linked to care within one month of diagnosis date—see Fig. 1 for relevant NHAS 
indicators), though one study did directly assess viral suppression (NHAS indicator 6). Most 
studies (5/7, 71%) identified the proportion of patients that ‘established’ care after new 
diagnosis—measures of establishing care included documentation of a clinic visit, 
laboratory test, or ART initiation within a set period of time (varied between 3 months and 1 
year). Effect sizes of interventions were largely reported as an absolute comparison of 
proportions (5/7, 71%), or relative measures such as hazard ratios or odds ratios (3/7, 43%). 
Alternatively, one study (14%) reported outcomes as a continuous measure of time until first 
visit.
Interventions were broadly categorized as involving case management (3/7, 43%, e.g. 
providing a case manager until an individual established HIV care), policy changes (2/7, 
29%, e.g. routine opt-out HIV testing), change in HIV testing modality (1/7, 14%, e.g. rapid 
vs conventional tests), and co-location of care (1/7, 14%, e.g. HIV medical care co-located 
with ARTAS II site). Efficacy of these differing strategies was mixed. Two (2/3, 66%) case 
management interventions showed statistically significant improvements in linkage to care, 
two (2/2, 100%) policy interventions and the one co-location of services study also showed 
improvement. However, the overall effect size of these interventions was modest and ranged 
from an incremental 3% to 24% linked compared to standard of care.
Retention
Among 33 total studies that targeted patients already established in care, 31 (94%) studies 
evaluated 35 separate interventions addressing retention in care, while the remaining two 
(6%) addressed only the costs of such interventions. Of the 31 intervention studies, 13 (42%) 
were RCTs, while 10 (32%) were cohort studies, and 8 (26%) were pre-post study designs. 
The target populations studied included PWUD (13% of studies), adolescents/youth (10%), 
young black and Latino MSM (6%), prison or jail populations (6%), and other target 
populations (23%); 42% lacked a pre-specified target risk group.
Overall, these 31 studies utilized 39 different measures to evaluate the impact of retention in 
care interventions, with each study measuring from 1–5 (median = 2) outcomes 
(Supplemental Table). These study outcomes could be broadly grouped into four categories: 
change in clinic visits within given period of time, change in the number of laboratory tests 
(such as CD4 count) within a given period of time, change in ART prescriptions or ART 
usage, and change in viral load/viral suppression. Follow-up times at which the outcome 
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assessments were made varied across studies. Methodology for reporting effect sizes was 
heterogeneous. Some studies reported dichotomized data (23/31, 74%) based on the number 
or percentage of the study participants that met the study definitions for being retained in 
care over the study period, while others reported continuous data (13/31, 42%, e.g. mean 
number or proportion of clinic visits kept). Eleven (35%) reported on the downstream care 
continuum target of viral suppression. The current NHAS progress indicator related to 
retention in care (NHAS indicator 5) seeks to engage (cross-sectionally) 90% of all 
diagnosed persons in care. Among the 31 intervention studies, 19 (61%) provided results in 
a format (i.e. proportion in care among intervention group) that would allow some 
comparison to this NHAS progress indicator, while only 3 (10%) used the precise outcome 
of retention (two care visits, 90 days apart, within the calendar year) listed by the NHAS.
Interventions studied by investigators were diverse (Table 2). The majority of interventions 
focused on implementing novel technology (7/31, 23%, example: text message appointment 
reminders, interactive clinical decision-support with alerts for poor patient outcomes), case 
management or outreach (8/31, 26%, example: enhanced personal contact, medical case 
management), or counseling/behavior modification strategies (8/31, 26%, example: 
motivational interviewing, peer mentoring).
A low proportion of studies that evaluated behavior modification/counseling (1/7, 14%) 
found significant improvements in care retention. By contrast, integration of services (5/5, 
100%), and to a lesser extent, case management (5/7, 71%), technology (5/7, 71%) and 
clinic-based interventions (4/6, 67%) all had higher proportions of potentially efficacious 
interventions according to the effect measures and outcomes chosen by the study 
investigators. The heterogeneity of these interventions, target groups, and effect measures 
precluded meta-analysis. Overall, the effect sizes of interventions with significant results 
(bold rows, Table 2) were modest, and few (3/31) assessed outcomes longitudinally over 
more than 1 year. Of the included studies and interventions that could be assessed against the 
NHAS progress indicator 5, only 4/19 (21%) reported achieving retention of 90% of study 
participants at 1 year (or the end of their study period).
Among the most rigorously designed studies (RCTs), only 3/13 (23%) reported significantly 
improved retention among the intervention groups. None (0/5, 0%) of the RCTs that 
centered on behavioral or counseling interventions demonstrated significant impact on care 
retention. The effect sizes and interventions among RCTs suggesting improvements in 
retention in care varied. Gardner et al. implemented an intervention for education and 
enhanced personal contact for a general HIV clinic population over 12 months and found 
that visit adherence (defined as proportion kept out of all scheduled primary care visits) 
increased from 67% to 73% [16]. By contrast, however, three other RCTs evaluating 
educationally focused interventions found no significant effect [17–19]. Lucas et al. found 
that clinic-based substance abuse treatment modestly improved the number of clinic visits 
over the twelve month study period from 3 to 3.5 when comparing control to intervention 
arms [20]. Robbins et al. studied a technology-based decision support intervention to alert 
providers to poor patient outcomes and found a 9.5 per 100 person year reduction in the 
rates of 6 month suboptimal follow-up [21]; two other technology-centered interventions, 
however, showed no significant change in retention in care [22, 23].
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Reengagement
Few studies (4) assessed reengagement in care (see Table 3), and none of these studies 
addressed costs. One of these was a cohort study, while the other three employed a pre-post 
study design. All four studies addressed general populations of PLHIV who were out of 
care. Intervention types were variable, and included provider notifications, policy (routine 
opt-out HIV screening), case management, collaboration between clinics and health 
departments, and navigation-like interventions. Reengagement studies reported on 8 
different outcomes; three of the four studies reported viral load or viral suppression as one of 
their outcomes. Three of these four studies found significant improvements in engagement in 
care following the intervention, though these significant impacts included a range of effect 
sizes (such as a 5% increase in re-linkage [24], 11.2% increase in viral suppression [25], and 
3.9–5.4% reduction in no care in the past 6 months [26]).
Adherence
Among 117 total studies evaluating interventions addressing medication adherence among 
patients in care, 111 adherence studies evaluated efficacy alone, 4 addressed costs alone, and 
2 addressed both efficacy and costs. Of the 113 efficacy studies, 65 (57%) were RCTs, while 
20 (18%) were cohort studies, and 28 (25%) were pre-post study designs. Nearly half of 
studies (53/113, 47%) targeted a general population of PLHIV taking ART, while 23 (20%) 
targeted PWUD, 9 (8%) targeted adolescents/youth and 8 (7%) targeted women. Only 2 
(2%) studies exclusively recruited MSM, and an additional 2 (2%) exclusively recruited 
racial minorities. Interventions ranged from adjunctive treatment for drug use, to active 
reminder systems (using technology) to clinic-wide interventions that were not individually 
targeted (Table 4).
Outcomes of interest ranged from adherence measures to biological outcomes, with 50% 
reporting on viral suppression as an outcome. Adherence was measured in numerous ways, 
including self-report [using several measures, including the visual analog scale (VAS) and 
the AIDS clinical trial group (ACTG) questionnaire], electronic pill bottles [such as 
Medication Event Monitoring System (MEMS) caps], pill counting, medication refills, and 
presence of antiretrovirals in specimens (such as hair or plasma). Some of these measures 
included a time component (proportion of doses taken on time), and measures used a variety 
of recall periods (3 days, 7 days, 3 weeks, etc.).
Efficacy of adherence interventions was extremely varied across and within intervention 
types (Table 4). While the greatest number of studies focused on counseling (37, 33%), half 
(51%) of these reported improved adherence and the remainder indicated no improvement or 
worsened adherence. NHAS progress indicator 6 calls for achieving 80% viral suppression 
among those diagnosed. In these cohorts of individuals that were diagnosed (and in care), 8 
studies (15% of the 52 studies for which it was possible to assess) reported intervention viral 
suppression results that met this target. Assessing virologic outcomes was limited by 
methodologic issues—for example, cutoffs for viral suppression varied from <20 to <400 
copies/ml (limiting comparability), some patients met criteria for viral suppression at some 
time points but not longitudinally, and some studies reported viral loads but did not formally 
assess viral suppression. Among the 8 studies that achieved at least 80% virologic 
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suppression [27–34], the types of interventions varied [3 directly administered ART 
(DAART), 2 behavioral/counseling, 2 pharmacy-based and 1 education], as did the target 
population being addressed (6 general, 1 women, 1 PWUD), and the type of study design (4 
RCTs, 1 cohort, 3 pre-post). Nonetheless, only four of these studies [27, 29, 32, 34] found a 
significant improvement in viral suppression in the intervention group versus the comparator 
group.
Study Quality
The quality of included studies varied substantially. Among the 74 included RCTs, most 
(63/74) reported random sequence generation though some (10/74) did not clearly describe 
their randomization method. Few studies clearly described concealment of treatment 
allocation (18/74). Very few RCTs (9/74) were completely blinded/-masked (largely due to 
the nature of interventions assessed), though few (21/74) used outcome assessors blinded/
masked to treatment assignment either. A high proportion of RCTs (31/74) were deemed to 
be at high risk of bias due to attrition from the studies. Among 73 observational studies, 
most (64/73) were assessed to be somewhat or truly representative of the population of 
interest. Most (49/73) collected outcomes by linking to medical records, with just over a 
quarter using self-reported outcomes (20/73). Observational studies also had high levels of 
attrition, with only 32/73 having over 90% follow-up. Among 31 cohort studies, most 
(26/31) accounted for confounding in their analyses.
Discussion
Successful strengthening of the care continuum will require combination of, and 
prioritization between, different interventions—tasks that are difficult without common 
metrics to evaluate the effect of interventions on outcomes. Our review highlights the 
tremendous degree of heterogeneity across existing studies to improve the HIV continuum 
of care. We found a high degree of heterogeneity when defining outcomes of interest, as well 
as in measuring effect sizes of interventions. Moreover, only 3/38 linkage and retention 
studies offered care engagement results in a format that could be compared to external 
metrics of success set forth in the newest NHAS. These elements of study heterogeneity 
threaten our ability to effectively select the combinations of interventions likely to have the 
greatest effect. Additionally, models suggest that as little as 3.3% of HIV transmissions in 
the US occur as a result of individuals on ART but not virally suppressed (the population 
targeted by adherence interventions) whereas the population diagnosed but not retained in 
care contribute as much as 61.3% of infections [35]. We reveal a disconnect between the 
areas of the HIV continuum of care where greatest impact could be achieved (retention and 
reengagement) and the areas where intervention evidence is strongest (adherence, 
representing 77% of studies identified). We identify a paucity of evidence to guide 
interventions targeting persons at high risk (e.g., MSM, transgender individuals), a gap 
which has been identified previously [36, 37]. Further, we identify few studies that present 
cost data, despite the widespread understanding that funders and health departments need 
these data in an era of largely flat budgets. These findings suggest a need for a consensus 
process to develop more clear guidance to the HIV research community about which types 
of interventions are in greatest need of study, which populations should be targeted, and 
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which outcomes should be measured in order to develop a more effective and coordinated 
HIV response in the US.
Overall, we found few consistent themes to suggest efficacy of specific interventions, or 
broader intervention types. Among studies of individuals in care, we found that a majority of 
studies that used integrated services (such as co-located substance abuse treatment with HIV 
treatment), case management, technology (such as provider alerts and automated messages 
to patients) and clinic-based interventions (such as clinic-wide messaging and bilingual care 
teams) had significantly improved results in retention. Financial incentives, active reminder 
devices, structural and pharmacy-based interventions had the highest proportion of 
significantly improved results among the included adherence studies. The CDC’s Prevention 
Research Synthesis compendium provides an excellent resource for policymakers looking to 
select an evidence-based intervention in their population of interest [13]. We note that given 
the heterogeneity in study populations and locally specific intervention details, that it is 
difficult to draw any conclusions about the generalizability of these intervention types across 
settings.
While the NHAS has outlined specific targets, which are laudable in outlining objective 
goals for providers, program managers, and researchers to assess progress along the HIV 
care continuum, we found that these metrics are mismatched to recent research efforts in 
important ways. For example, NHAS indicators for care retention and viral suppression 
(indicators 5 and 6) have denominators of all individuals who are diagnosed with HIV, while 
in general, retention and adherence studies have denominators of people who are in care. In 
order for researchers or program managers to easily compare their results of a retention or 
adherence intervention to these measures, they would have to extrapolate to the proportion 
diagnosed instead of directly comparing their data.
Beyond the challenges to comparing intervention effects with NHAS indicators, we found 
no consensus in how to define or measure any stage of engagement along the HIV care 
continuum. First, we found 11 different outcomes used in the literature to assess initial 
linkage to care, and 39 different outcomes among retention in care studies. This 
heterogeneity makes it very difficult to compare interventions or intervention types, and 
precludes our ability to draw any solid conclusions regarding intervention efficacy. While 
work has been done to consolidate definitions [38], this is not resulting in consolidation 
among researchers. Second, achieving 80% viral suppression among those diagnosed is part 
of the NHAS (indicator 6), but only 1/7 (14%) studies of linkage interventions, 11/31 (35%) 
studies of retention interventions, and only 56/113 (50%) studies of adherence interventions 
evaluated improvements in achieving the ultimate goal of viral suppression. By measuring 
‘upstream’ effects, it is not possible to assess the net benefit of a care continuum 
intervention, which may be compromised by gaps in downstream care engagement (i.e., 
interventions showing incremental increases in initial linkage to care may have reduced net 
benefits due to poor downstream longitudinal retention in care). Third, compounding the 
challenge in evaluating the literature is the lack of standardization in how intervention 
efficacy is assessed. Beyond variability in defining outcomes of interest, researchers 
assessed intervention effects in a varied manner; as such, we were unable to provide pooled 
estimates of incremental benefit for any specific interventions. Finally, engagement in HIV 
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care is dynamic over time and continuous retention and viral suppression is needed to reduce 
transmission and improve health [39]. As such, cross-sectional or short-term assessments of 
care engagement may misrepresent longitudinal efficacy. In our review, we found that very 
few studies assessed outcomes beyond a few months.
Throughout our analysis, we have highlighted the relative distribution of RCTs to 
observational studies, recognizing that observational study designs may have greater risk of 
some biases. However, it is important to note that causal inference methods have made 
tremendous strides to allow observational studies to better approximate randomized designs 
through novel analytic methods and designs which take advantage of “natural experiments.” 
Such novel methods of analysis or study designs would be a benefit to the care continuum 
research community, and appear to be under-utilized. For instance, propensity score 
matching, a method to make groups exposed and unexposed to an intervention as 
comparable as possible in observational studies, was used by only 4 cohort studies out of 31 
included in our review. Other methods that take advantage of natural experiments or changes 
over time, such as instrumental variables, regression discontinuity, and interrupted time 
series could also help in providing valid causal inference regarding the effect of studied 
interventions. Given some of the resource and practical challenges of incorporating 
randomized trial designs into implementation research on care continuum interventions, 
investigators may wish to consider incorporation of alternative novel study designs and 
analytic methods in the future.
Given our findings, we recommend several steps be taken in order to improve the evidence 
base for strengthening HIV care engagement in the US. First, researchers, health 
departments and funders must come to consensus on definitions for linkage, retention and 
reengagement in care, and ART adherence for the purposes of scientific investigation. 
Second, we would propose that irrespective of the step in the care continuum being targeted, 
that a central outcome of interest (in addition to the proximal impact of an intervention) is 
the incremental number or percentage of individuals achieving viral suppression (over a 
defined period of time, such as a year). Since directly studying viral suppression may not be 
feasible in a study of ‘upstream’ interventions (such as linkage interventions), we propose 
that a tool be developed to aid researchers to translate upstream interventions to viral 
suppression outcomes. Such a tool or calculator would incorporate locally specific care 
continuum data to allow translation of incremental impact from upstream interventions into 
an incremental change in viral suppression; while such an approach would require several 
assumptions and have limitations, it would allow a common framework to measure care 
continuum interventions. By utilizing a consensus downstream effect measure, one begins to 
be able to compare absolute levels of benefit of interventions at varying stages in the care 
continuum. Third, studies of novel care continuum interventions need carefully constructed 
study designs. We found that over 1/3 of studies identified for full text review in this study 
(see Appendix for PRISMA diagram) were excluded because of a lack of a defined 
comparator group (i.e. one armed studies) or lack of quantifiable outcomes. Studies should 
clearly define the intervention, population under study, and distinguish the intervention 
group from a comparator group unexposed to the intervention, while clearly defining the 
comparator (for instance, “standard of care” needs to be explicitly defined). While 
qualitative information about interventions is vital to understanding aspects of acceptability, 
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usability, and scalability, quantifiable outcomes and standard measures of effect size should 
be established. Fourth, the vast majority of interventions (95%) addressed only a single step 
of the care continuum, which fails to capture that care is lifelong and involves ongoing 
engagement and movement between continuum “steps.” Therefore, we recommend that 
where possible, integration of different steps of the care continuum be assessed. In 
conjunction with this suggestion, we acknowledge that within a given step of the care 
cascade, multiple intervention modalities could be implemented; thus far, a minority of 
studies implemented multi-modal interventions. It is unclear whether combination 
interventions will result in independent effects, and as such testing combination 
interventions should be prioritized. Moreover, while many of the absolute effect sizes for 
interventions were small, these effects could offer meaningful impact when scaled-up at a 
population level; future studies may consider incorporation of modeling approaches that 
allows one to extrapolate the potential impact of HIV care continuum strengthening at a 
population level. Fifth, we recommend that observational designs increasingly use 
appropriate causal inference methods and study designs where possible to allow greater 
confidence in the results of these studies. Finally, as the care continuum is dynamic over 
time, we propose that reporting of longitudinal measures of care continuum outcomes be 
prioritized. As an example, reporting the incremental change in the rate of loss from care per 
unit time (as a metric for evaluating interventions to improve retention in care) would allow 
a more comprehensive understanding of intervention efficacy; currently most reported 
outcomes in the studies identified in this review were limited by their cross-sectional nature 
and short time period for follow up.
Our review has several important limitations. First, in order to offer a comprehensive picture 
of all research studying interventions to strengthen the HIV continuum of care, we present 
studies of highly varying quality (for instance RCTs vs pre-post design, and with substantial 
variability within each of those design types) without an attempt to exclude low-quality 
studies. Other reviews (with different purposes) restrict themselves exclusively to 
interventions with a high-quality evidence base and the CDC Prevention Research Synthesis 
Team has compiled this data to promote best practices, despite limited data [7, 9, 13]. 
Second, since our purpose was to characterize the breadth of HIV care continuum 
interventions, we also were not able to evaluate any specific set of interventions (e.g. those 
related to adherence) in substantial depth. Other systematic reviews [7–10] have aimed to fill 
this gap. Third, due to the substantial variability in outcomes, study design, and target 
populations, we were unable to conduct a meta-analysis. The heterogeneity that we 
characterize, however, can help motivate HIV researchers to unify their methodology to 
enable future research to be more easily summarized. Additionally, we had no limit for the 
year of implementation of the study (only for year of publication) so some findings may be 
less relevant for the current care context.
In conclusion, this systematic review of over 150 interventions to strengthen the continuum 
of HIV care in the US highlights a small number of effective interventions but more 
importantly reveals tremendous heterogeneity in methodology and outcome assessment. 
Furthermore, there is a paucity of data on linkage and reengagement, less evidence on 
retention than adherence, and few studies targeting populations experiencing the highest 
incidence of HIV in the US (MSM, particularly black and Latino MSM). If we are to 
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develop a coordinated strategy to achieve the ambitious NHAS targets, increased attention 
must be paid to filling the biggest gaps in the current continuum of care. Researchers must 
also report outcomes in a standardized fashion—with focus on the ultimate outcome of viral 
suppression—that will enable combination and prioritization. The current piecemeal 
approach to HIV continuum research must be improved; by looking at the HIV continuum of 
care from an integrated, top-down perspective, a more comprehensive strategy can be 
created to end the HIV epidemic in the US.
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Fig. 1. 
Schematic of HIV care continuum in the United States indicating steps of interest in review, 
and summary of outcomes in review. Each box’s area is proportionally sized to the United 
States population of people living with HIV in 2012 [5, 173]. Boxes representing very small 
proportions of the population (Newly Diagnosed and Newly in Care) are enlarged for 
purposes of display. Table displays the continuum steps of interest in review, number of 
studies included in review (N), NHAS indicator relevant to the continuum step, and a 
sampling of the outcomes identified in included studies in the review (for full list of 
outcomes identified, please see Supplemental Table)
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